Previous 10 | Next 10 |
TEL AVIV, Israel and NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today ann...
TEL AVIV, Israel and NEW YORK, May 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announce...
Gainers: SQZ Biotechnologies (SQZ) +20%. Amedisys (AMED) +7%. Thermo Fisher Scientific (TMO) +7%. Vascular Biogenics (VBLT) +5%. Opiant Pharmaceuticals (OPNT) +4%. Losers: Teladoc Health (TDOC) -46%. Align Technology (ALGN) -23%. Aptorum Group (APM) -19...
What To Know About Buying Penny Stocks on April 26th With so many penny stocks to choose from, it can seem difficult to pick the best ones to buy. However, because there is such a large variety of small caps out there, finding ones that have the opportunity to be profitable, is complete...
The U.S. Food and Drug Administration (FDA) granted fast track designation to VBL Therapeutics' (NASDAQ:VBLT) ofra-vec (ofranergene obadenovec or VB-111) in combination with chemotherapy paclitaxel to treat platinum-resistant ovarian cancer. The company said it has completed enrollm...
Jiuzi Holdings (JZXN) +88% enters into an equity acquisition agreement to acquire automobile sales serviceshop operator under top China automaker Geely Auto's premium electronic vehicle brand geometry. Avadel Pharmaceuticals (AVDL) +35% provides comment on Recent trading activity. Gamida...
FDA grants Fast Track designation to facilitate development and expedite the review of therapies with potential to treat serious unmet medical needs. The purpose of this designation is to bring important new drugs to patients earlier OVAL Phase 3 top-line progression free survival...
The following slide deck was published by Vascular Biogenics Ltd. in conjunction with this event. For further details see: Vascular Biogenics (VBLT) Presents at the KOL Event on Ovarian Cancer - Slideshow
Three leading experts in gynecological oncology will discuss treatment landscape and unmet needs in ovarian cancer Event on Monday, April 11, 2022 at 12pm EDT in New York City TEL AVIV, Israel and NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (VBL), ...
Vascular Biogenics Ltd. (VBLT) Q4 2021 Earnings Conference Call March 22, 2022 8:30 a.m. ET Company Participants Dror Harats - CEO Sam Backenroth - CFO Dan Ferry - LifeSci Advisors, IR Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Susan Chor - Oppenheimer & Co. Swa...
News, Short Squeeze, Breakout and More Instantly...
Vascular Biogenics Ltd. Company Name:
VBLT Stock Symbol:
NASDAQ Market:
Approved Merger with Notable Labs and All Other Proposals Merger Expected to Close and Begin Trading as Combined Company Under the NTBL Ticker on Nasdaq Next Week, Subject to Effectiveness of Approved Israeli Corporate Actions MODI’IN, Israel and NEW YORK, Oct. 12, 2023 (GL...
MODI’IN, Israel and NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), reminds its shareholders to vote in favor of the previously announced proposed merger (the “Merger”) with Notable Labs (“Notable”) at the annua...
Merger with Notable expected to close in mid-October, subject to shareholder approval Special shareholder meeting scheduled for October 12, 2023 MODI’IN, Israel and NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), today ann...